EUCTR2011-000954-46-DE
Active, not recruiting
Not Applicable
An open-label, single-arm, phase II, multicenter study to evaluatethe efficacy of vemurafenib in metastatic melanoma patients with brain metastases - NA (no short title)
F. Hoffman-La Roche Ltd.0 sites132 target enrollmentMay 31, 2011
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- F. Hoffman-La Roche Ltd.
- Enrollment
- 132
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients, \= 18 years of age
- •Metastatic melanoma (Stage IV, American Joint Committee on Cancer) with BRAF V600 mutation (cobas 4800 BRAF V600 Mutation Test)
- •Measurable brain metastases, treated or untreated
- •Patients may or may not have received prior systemic therapy for metastatic melanoma and either a) have received no prior treatment for brain metastases or b) have received prior treatment for brain metastases and have progressed
- •Patients may or may not have symptoms related to their brain metastases
- •Eastern Cooperative Oncology Group (ECOG) performance status 0\-1
- •Patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •Increasing corticosteroid dose during the 7 days prior to first dose of study drug
- •Leptominingeal involvement in patients with no prior treatment for brain metastases (cohort 1\). Leptomeningeal involvement is only allowed in patients with prior treatment for brain metastases (cohort 2\)
- •Previous malignancy requiring active treatment within the past 2 years, except for treated and controlled basal or squamous cell carcinoma of the skin, or carcinoma in\-situ of the cervix
- •Concurrent administration of any anticancer therapies other than those administered in the study
- •Treatment with any cytotoxic and/or investigational cytotoxic drug or targeted therapy \= 4 weeks prior to first administration of vemurafenib and radiation therapy \= 1 weeks prior to first administration of vemurafenib and stereotactic radiotherapy \= 1 day prior to prior to first administration of vemurafenib.
- •Prior treatment with BRAF or MEK inhibitors
- •Clinically significant cardiovascular disease or event within the 6 months prior to first dose of study drug
- •History or presence of clinically significant cardiac dysrhythmia
- •Corrected QT interval \= 450 ms or history of congenital long QT syndrome
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Este estudio abierto evaluará la eficacia y seguridad de vemurafenib (RO5185426) en pacientes con melanoma metastásico con metástasis cerebrales tratadas o no tratadas. Los pacientes recibirán vemurafenib (RO5185426) oralmente a una dosis de 960 mg dos veces al día hasta progresión de la enfermedad o toxicidad inaceptable.Metastatic Melanoma with Brain MetastasesMedDRA version: 14.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000954-46-ESF. Hoffmann-La Roche Ltd.132
Completed
Phase 2
An open-label, single-arm, phase II, multicenter study to evaluate;the efficacy of vemurafenib in metastatic melanoma patients with brain metastasesaggressive skin cancermetastatic melanoma10027476NL-OMON37956Roche Nederland B.V.14
Active, not recruiting
Phase 1
An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastasesMetastatic Melanoma with Brain MetastasesMedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000954-46-ITROCHE146
Completed
Phase 2
An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of nivolumab in metastatic melanoma patients with symptomatic brain metastases.advanced melanomaMetastatic melanoma10027476NL-OMON42782niversitair Medisch Centrum Groningen70
Active, not recruiting
Phase 1
This open-label study will assess the efficacy and safety of vemurafenib (RO5185426) in metastatic melanoma patients with untreated or treated brain metastases. Patients will receive vemurafenib (RO5185426) at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.Metastatic Melanoma with Brain MetastasesMedDRA version: 14.1 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000954-46-GBF. Hoffman-La Roche Ltd.146